• Executive Summary
o Market overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2020
o Market outlook: Forecast for 2020 – 2025
• Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by Product
o Market segments
o Comparison by Product
o Conventional vaccines – Market size and forecast 2020-2025
o Emergency vaccines – Market size and forecast 2020-2025
o Market opportunity by Product
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o Asia – Market size and forecast 2020-2025
o Europe – Market size and forecast 2020-2025
o North America – Market size and forecast 2020-2025
o ROW – Market size and forecast 2020-2025
o Key leading countries
o Market opportunity By Geographical Landscape
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Vendor landscape
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Biogenesis Bago SA
o Boehringer Ingelheim International GmbH
o Ceva Sante Animale
o Indian Immunologicals Ltd.
o Inovio Pharmaceuticals Inc.
o Merck & Co. Inc.
o SEPPIC SA
o VECOL SA
o VETAL Animal Health Products Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations
Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2020 – 2025 ($ million)
• 13: Global market: Year-over-year growth 2020 – 2025 (%)
• 14: Five forces analysis 2020 & 2025
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2020
• 21: Product – Market share 2020-2025 (%)
• 22: Comparison by Product
• 23: Conventional vaccines – Market size and forecast 2020-2025 ($ million)
• 24: Conventional vaccines – Year-over-year growth 2020-2025 (%)
• 25: Emergency vaccines – Market size and forecast 2020-2025 ($ million)
• 26: Emergency vaccines – Year-over-year growth 2020-2025 (%)
• 27: Market opportunity by Product
• 28: Customer landscape
• 29: Market share By Geographical Landscape 2020-2025 (%)
• 30: Geographic comparison
• 31: Asia – Market size and forecast 2020-2025 ($ million)
• 32: Asia – Year-over-year growth 2020-2025 (%)
• 33: Europe – Market size and forecast 2020-2025 ($ million)
• 34: Europe – Year-over-year growth 2020-2025 (%)
• 35: North America – Market size and forecast 2020-2025 ($ million)
• 36: North America – Year-over-year growth 2020-2025 (%)
• 37: ROW – Market size and forecast 2020-2025 ($ million)
• 38: ROW – Year-over-year growth 2020-2025 (%)
• 39: Key leading countries
• 40: Market opportunity By Geographical Landscape ($ million)
• 41: Impact of drivers and challenges
• 42: Vendor landscape
• 43: Landscape disruption
• 44: Industry risks
• 45: Vendors covered
• 46: Market positioning of vendors
• 47: Biogenesis Bago SA – Overview
• 48: Biogenesis Bago SA – Product and service
• 49: Biogenesis Bago SA – Key offerings
• 50: Biogenesis Bago SA – Key customers
• 51: Biogenesis Bago SA – Segment focus
• 52: Boehringer Ingelheim International GmbH – Overview
• 53: Boehringer Ingelheim International GmbH – Business segments
• 54: Boehringer Ingelheim International GmbH – Key offerings
• 55: Boehringer Ingelheim International GmbH – Key customers
• 56: Boehringer Ingelheim International GmbH – Segment focus
• 57: Ceva Sante Animale – Overview
• 58: Ceva Sante Animale – Product and service
• 59: Ceva Sante Animale – Key offerings
• 60: Ceva Sante Animale – Key customers
• 61: Ceva Sante Animale – Segment focus
• 62: Indian Immunologicals Ltd. – Overview
• 63: Indian Immunologicals Ltd. – Product and service
• 64: Indian Immunologicals Ltd. – Key offerings
• 65: Indian Immunologicals Ltd. – Key customers
• 66: Indian Immunologicals Ltd. – Segment focus
• 67: Inovio Pharmaceuticals Inc. – Overview
• 68: Inovio Pharmaceuticals Inc. – Product and service
• 69: Inovio Pharmaceuticals Inc. – Key offerings
• 70: Inovio Pharmaceuticals Inc. – Key customers
• 71: Inovio Pharmaceuticals Inc. – Segment focus
• 72: Merck & Co. Inc. – Overview
• 73: Merck & Co. Inc. – Business segments
• 74: Merck & Co. Inc. – Key offerings
• 75: Merck & Co. Inc. – Key customers
• 76: Merck & Co. Inc. – Segment focus
• 77: SEPPIC SA – Overview
• 78: SEPPIC SA – Product and service
• 79: SEPPIC SA – Key offerings
• 80: SEPPIC SA – Key customers
• 81: SEPPIC SA – Segment focus
• 82: VECOL SA – Overview
• 83: VECOL SA – Product and service
• 84: VECOL SA – Key offerings
• 85: VECOL SA – Key customers
• 86: VECOL SA – Segment focus
• 87: VETAL Animal Health Products Inc. – Overview
• 88: VETAL Animal Health Products Inc. – Product and service
• 89: VETAL Animal Health Products Inc. – Key offerings
• 90: VETAL Animal Health Products Inc. – Key customers
• 91: VETAL Animal Health Products Inc. – Segment focus
• 92: Currency conversion rates for US$
• 93: Research Methodology
• 94: Validation techniques employed for market sizing
• 95: Information sources
• 96: List of abbreviations
❖ 掲載企業 ❖
Biogenesis Bago SA, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Indian Immunologicals Ltd., Inovio Pharmaceuticals Inc., Merck & Co. Inc., SEPPIC SA, VECOL SA, VETAL Animal Health Products Inc.